WASHINGTON — One of the Food and Drug Administration’s top officials says that consolidation in the drug distributor market has made it less attractive for companies to sell generic drugs — and that raising prices of the drugs might actually invite more competition.

“This is a silent crisis,” said Janet Woodcock, director of the Center for Drug Evaluation and Research, said Friday. “It’s very bad.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Another “Crisis” created by Industry Insiders and Pharma Lobbyists. We need to Privatize these operations to ensure a steady supply of inexpensive medications. Clearly the Industry has run it’s course. If it weren’t for these insiders and the corrupt politicians we would not be here now.

  • This is actually an old issue we have dealt with over many years and makes sense. Having sat on Pharmacy GPO Committees while in hospital practice, working at a GPO and in industry with some generic SKUs and drugs, we dealt with this. In industry, we actually tried to negotiate a highe price model, with guaranteed supply. Selling drugs as a lost leader at or below manufacturing cost is a poor clinical/financial model. Number one, we need drugs to treat patients and two, what is fair market value.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy